A Madison drug development company said Thursday it has received a $986,000 Small Business Innovation Research grant from the National Cancer Institute.
Quintessence Biosciences Inc. will use the money to support development of more drugs based on its Evade Ribonuclease technology, the company said.
Ribonuclease is a protein that chews up RNA, the long strands of material that transmit messages for cells. The company's technology aims to kill cancer cells by destroying the link between their DNA and protein.
